{"id":"linzagolix","rwe":[{"pmid":"41874853","year":"2026","title":"Insights on Medical Therapy for Uterine Fibroids: A Review.","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"},{"pmid":"41722022","year":"2026","title":"NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties.","finding":"","journal":"PharmacoEconomics","studyType":"Clinical Study"},{"pmid":"41306462","year":"2025","title":"Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials.","finding":"","journal":"International journal of reproductive biomedicine","studyType":"Clinical Study"},{"pmid":"41133175","year":"2025","title":"Sequential and Personalized Linzagolix Therapy for Uterine Fibroids: A Rational Clinical Approach.","finding":"","journal":"Women's health reports (New Rochelle, N.Y.)","studyType":"Clinical Study"},{"pmid":"40777872","year":"2025","title":"Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.","finding":"","journal":"Przeglad menopauzalny = Menopause review","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"H01CC04","category":"atc"},{"label":"Active","category":"status"},{"label":"Uterine fibroids","category":"indication"},{"label":"Obseva Ireland Ltd","category":"company"}],"phase":"marketed","safety":{"contraindications":["Breastfeeding (mother)","Genital bleeding","Osteoporosis","Pregnancy, function"]},"trials":[],"aliases":[],"company":"Obseva Ireland Ltd","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LINZAGOLIX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:27.016252+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Linzagolix","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:12:34.283133+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:12:43.357218+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:32.700606+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:12:27.083899+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LINZAGOLIX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:33.239979+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Gonadotropin-releasing hormone receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:34.283076+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3668014/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:33.948861+00:00"}},"allNames":"yselty","offLabel":[],"synonyms":["linzagolix","linzagolix choline","yselty","OBE2109","KLH-2109"],"timeline":[{"date":"2022-06-14","type":"positive","source":"DrugCentral","milestone":"EMA approval (Obseva Ireland Ltd)"}],"aiSummary":"LINZAGOLIX (Yselty), marketed by Obseva Ireland Ltd, is a gonadotropin-releasing hormone receptor antagonist indicated for the treatment of uterine fibroids. Its key strength lies in its mechanism of action, which effectively reduces the growth and size of uterine fibroids, positioning it as a competitive alternative to off-patent drugs like ganirelix and cetrorelix. The primary risk is the strong competition from other patent-protected drugs such as elagolix, which has a patent expiry in 2036, and estradiol, with a patent expiry in 2032.","approvals":[{"date":"2022-06-14","orphan":false,"company":"OBSEVA IRELAND LTD","regulator":"EMA"}],"brandName":"Yselty","ecosystem":[{"indication":"Uterine fibroids","otherDrugs":[{"name":"norethindrone acetate","slug":"norethindrone-acetate","company":"Warner Chilcott Llc"},{"name":"relugolix","slug":"relugolix","company":"Myovant Sciences"}],"globalPrevalence":17600000}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Yselty is a selective GnRH receptor antagonist that competitively binds to the GnRH receptor, preventing the binding of endogenous GnRH and subsequent activation of downstream signaling pathways involved in the regulation of the menstrual cycle and uterine fibroid growth."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Linzagolix","title":"Linzagolix","extract":"Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids and endometriosis. Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist developed by Kissei Pharmaceutical and ObsEva.","wiki_society_and_culture":"==Society and culture==\n=== Legal status ===\nOn 16 December 2021, and on 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yselty, intended for the treatment of symptoms of uterine fibroids. Linzagolix was approved for medical use in the European Union in June 2022."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5701","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LINZAGOLIX","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LINZAGOLIX","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Linzagolix","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T12:22:12.153549","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:12:43.357305+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ganirelix","drugSlug":"ganirelix","fdaApproval":"1999-07-29","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cetrorelix","drugSlug":"cetrorelix","fdaApproval":"2000-08-11","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elagolix","drugSlug":"elagolix","fdaApproval":"2018-07-23","patentExpiry":"Sep 1, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"norethisterone","drugSlug":"norethisterone","fdaApproval":"1962-05-21","relationship":"same-class"},{"drugName":"relugolix","drugSlug":"relugolix","fdaApproval":"2020-12-18","patentExpiry":"Sep 29, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"linzagolix","indications":{"approved":[{"name":"Uterine fibroids","source":"DrugCentral","snomedId":95315005,"regulator":"FDA","globalPrevalence":17600000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Front Reprod Health, 2021 (PMID:36304010)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ganirelix","brandName":"ganirelix","genericName":"ganirelix","approvalYear":"1999","relationship":"same-class"},{"drugId":"cetrorelix","brandName":"cetrorelix","genericName":"cetrorelix","approvalYear":"2000","relationship":"same-class"},{"drugId":"elagolix","brandName":"elagolix","genericName":"elagolix","approvalYear":"2018","relationship":"same-class"},{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-class"},{"drugId":"norethisterone","brandName":"norethisterone","genericName":"norethisterone","approvalYear":"1962","relationship":"same-class"},{"drugId":"relugolix","brandName":"relugolix","genericName":"relugolix","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07015268","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Patients With Endometriosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2025-06-09","conditions":["Endometriosis"],"enrollment":288,"completionDate":"2027-11"},{"nctId":"NCT05445167","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2022-10-11","conditions":["Uterine Fibroids (MeSH Heading: Leiomyoma)"],"enrollment":89,"completionDate":"2024-02-16"},{"nctId":"NCT04335591","phase":"PHASE3","title":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2020-03-05","conditions":["Endometriosis"],"enrollment":356,"completionDate":"2022-12-15"},{"nctId":"NCT04372121","phase":"PHASE3","title":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2020-03-23","conditions":["Endometriosis"],"enrollment":30,"completionDate":"2021-02-16"},{"nctId":"NCT03992846","phase":"PHASE3","title":"Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-06-13","conditions":["Endometriosis"],"enrollment":486,"completionDate":"2022-04-01"},{"nctId":"NCT03986944","phase":"PHASE3","title":"A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-05-23","conditions":["Endometriosis"],"enrollment":85,"completionDate":"2021-02-16"},{"nctId":"NCT05440383","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2022-10-11","conditions":["Uterine Fibroids (MeSH Heading: Leiomyoma)"],"enrollment":287,"completionDate":"2024-08-21"},{"nctId":"NCT02778399","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2016-07","conditions":["Endometriosis"],"enrollment":328,"completionDate":"2019-07-01"},{"nctId":"NCT03070899","phase":"PHASE3","title":"Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-04-20","conditions":["Uterine Fibroids","Heavy Menstrual Bleeding"],"enrollment":526,"completionDate":"2021-04-12"},{"nctId":"NCT03070951","phase":"PHASE3","title":"Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-05-23","conditions":["Uterine Fibroids","Heavy Menstrual Bleeding"],"enrollment":511,"completionDate":"2020-10-04"},{"nctId":"NCT03961932","phase":"PHASE1","title":"Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2019-05-15","conditions":["Renal Impairment","Healthy Participants"],"enrollment":33,"completionDate":"2020-01-31"},{"nctId":"NCT03962049","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2019-05-15","conditions":["Hepatic Impairment","Healthy Participants"],"enrollment":24,"completionDate":"2019-11-01"},{"nctId":"NCT02778919","phase":"PHASE2","title":"Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2016-05-09","conditions":["Endometriosis"],"enrollment":0,"completionDate":"2018-03-23"},{"nctId":"NCT01533532","phase":"PHASE2","title":"A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Endometriosis"],"enrollment":100,"completionDate":""},{"nctId":"NCT01629420","phase":"PHASE2","title":"A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Endometriosis"],"enrollment":20,"completionDate":""},{"nctId":"NCT01395940","phase":"PHASE2","title":"A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Endometriosis"],"enrollment":20,"completionDate":""}],"_emaApprovals":[{"date":"2022-06-14","status":"Authorised","company":"OBSEVA IRELAND LTD"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7CDW97HUEX","INN_ID":"10711","RXNORM":"2621019","UMLSCUI":"C5235403","chemblId":"CHEMBL3668014","ChEMBL_ID":"CHEMBL3668014","KEGG_DRUG":"D11608","DRUGBANK_ID":"DB17083","PUBCHEM_CID":"16656889","IUPHAR_LIGAND_ID":"12283","SECONDARY_CAS_RN":"1321816-57-2","MESH_SUPPLEMENTAL_RECORD_UI":"C000716911"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Obseva Ireland Ltd","relationship":"Original Developer"}],"publicationCount":55,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H01CC04","allCodes":["H01CC04"]},"biosimilarFilings":[],"originalDeveloper":"Obseva Ireland Ltd","recentPublications":[{"date":"2026 Mar 24","pmid":"41874853","title":"Insights on Medical Therapy for Uterine Fibroids: A Review.","journal":"Advances in therapy"},{"date":"2026 Feb 21","pmid":"41722022","title":"NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties.","journal":"PharmacoEconomics"},{"date":"2025 Sep","pmid":"41306462","title":"Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials.","journal":"International journal of reproductive biomedicine"},{"date":"2025","pmid":"41133175","title":"Sequential and Personalized Linzagolix Therapy for Uterine Fibroids: A Rational Clinical Approach.","journal":"Women's health reports (New Rochelle, N.Y.)"},{"date":"2025 Jun","pmid":"40777872","title":"Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.","journal":"Przeglad menopauzalny = Menopause review"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Obseva Ireland Ltd","companyId":"obseva-ireland-ltd","modality":"Small molecule","firstApprovalDate":"2022","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:12:43.357305+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}